POLYCOR: phase 2 clinical trial including more than 350 patients and the industrial scale-up of the production of XAV-19

The biotech XENOTHERA, the Nantes University Hospital and the University of Nantes announce the signing of a consortium agreement within the framework of a PSPC-COVID, operated on behalf of the State by Bpifrance within the framework of the Program d ' Investments for the Future, led by the General Secretariat for Investment (SGPI), in order to support XAV-19, XENOTHERA's anti-COVID-19 treatment, intended for patients at the start of hospitalization. The project, called POLYCOR, covers the completion of a phase 2 clinical trial including more than 350 patients and the industrial scale-up of the production of XAV-19. This amount will finance a phase 2 clinical trial promoted by the Nantes University Hospital, a fundamental research program by teams from the University of Nantes, and the acceleration of the production capacities of glyco-humanized antibodies by XENOTHERA. The POLYCOR clinical trial will take place in more than thirty hospitals across France and will be managed by clinical teams from the Nantes University Hospital, led by Professor François Raffi. Beyond the clinical trial, the POLYCOR project covers research activities on the immunology of COVID-19 infection, which will be carried out jointly by teams from the Nantes University Hospital and the University of Nantes, under the impulse of Ms. Sophie Brouard, Research Director at the CNRS. XENOTHERA's XAV-19 treatment is based on a unique, patented technology to produce protective polyclonal antibodies similar to the natural human response. The Nantes-based biotech has been working on coronavirus infections for more than four years, in parallel with its other products in transplantation, infectious diseases and oncology.